Fig. 3.

Driver gene mutations and copy number aberrations are not associated with clinical benefit of ACT in melanoma a. Mutations in melanoma driver genes in tumors from patients without (left) and with (right) clinical benefit from ACT. There is no significant difference in mutation frequency between the groups in any of the genes, as shown on the right by the P-values from logistic regression with adjustment for mutational load of samples. b Fraction of exons with copy number changes for tumors from patients with and without clinical benefit. P-value from Mann–Whitney test. In this standard boxplot, the center line represents the median, the box limits represent the lower and upper quartiles, the whiskers extend to the most extreme values within 1.5xIQR. RECIST categories: CR complete response; PD progressive disease; PR partial response; SD stable disease